Merck Arcoxia user fee deadline
User fee date for Merck's COX-2 inhibitor Arcoxia (etoricoxib) is Nov. 13, assuming FDA accepts the NDA for filing by March 12. Delay extends user fee deadline by two weeks; Merck told investors it submitted the Arcoxia NDA Dec. 30, but FDA now considers Jan. 13 the effective submission date...
You may also be interested in...
With list due 4 November, there may not be time for public comment. Meanwhile, where will biopharma find fill/finish capacity?
Lorbrena is approved as a second-line treatment for ALK-positive NSCLC but Pfizer believes data from the first-line Phase III CROWN study makes the drug a serious competitor to standard of care Alecensa in the first-line setting.
A new analysis of the ADAURA study shows that Tagrisso’s disease-free survival benefits in early stage EGFRm NSCLC are replicated for brain metastases, a common complication with a poor prognosis. Filings and OS data await.